Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586830 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
A Phase 2 study of Obesity and Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
- 20
- Study locations
NCT03586830 is a Phase 2 study of Obesity and Diabetes Mellitus, Type 2 that has completed, run by Janssen Research & Development. The registered enrollment target is 196 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT03586830, a Phase 2 study of Obesity and Diabetes Mellitus, Type 2, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from baseline and safety and tolerability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-64565111 Dose Level 1
- DRUG JNJ-64565111 Dose Level 2
- DRUG JNJ-64565111 Dose Level 3
Study Locations (20)
California
- National Research Institute - Los Angeles
- Rancho Cucamonga Clinical Trials - Rancho Cucamonga
- Sierra Clinical Research - Roseville
- Encompass Clinical Research - Spring Valley
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Premeir Clinical Research Institute - Miami
- International Research Associates, LLC - Miami
- CNS HealthCare - Orlando
- Translational Research Institute for Metabolism and Diabetes - Orlando
Ohio
- Prestige Clinical Research - Franklin
- Albert J. Weisbrot and Associates - Mason
Pennsylvania
- Clinical Research Associates of Central PA, LLC - Altoona
- Heritage Valley Medical Group - Beaver
Alabama
- Central Research Associates, Inc. - Birmingham
Indiana
- Buynak Clinical Research - Valparaiso
Kansas
- Cotton-O'Neil Clinical Research Center - Topeka
Maryland
- M.D. Medical Research - Oxon Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2019-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03586830
The ClinicalTrials.gov registry entry for NCT03586830 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity and Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03586830 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT03586830 about?
NCT03586830 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus". The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from baseline and safety and tolerability.
What is the current status of trial NCT03586830?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2018-06-26. Estimated completion is 2019-04-05.
What conditions does trial NCT03586830 study?
This clinical trial studies the following conditions: Obesity and Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03586830?
The interventions under investigation include: Placebo (DRUG), JNJ-64565111 Dose Level 1 (DRUG), JNJ-64565111 Dose Level 2 (DRUG), JNJ-64565111 Dose Level 3 (DRUG).
Who is sponsoring clinical trial NCT03586830?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03586830 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity and Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.